Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.

Keir, Stephen T; Morton, Christopher L; Wu, Jianrong; Kurmasheva, Raushan T; Houghton, Peter J; Smith, Malcolm A

Keir, Stephen T; Morton, Christopher L; Wu, Jianrong; Kurmasheva, Raushan T; Houghton, Peter J; Smith, Malcolm A.

Affiliation

Keir ST; Duke University Medical Center, Durham, North Carolina, USA. keir0001@mc.duke.edu

Pediatr Blood Cancer ; 59(3): 586-8, 2012 Sep.

Article in En | MEDLINE | ID: mdl-22190407

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Protein Kinase Inhibitors/therapeutic use; Pyrimidines/therapeutic use; Rhabdomyosarcoma/drug therapy; Sulfonamides/therapeutic use; Vascular Endothelial Growth Factors/antagonists & inhibitors; Animals; Cell Line, Tumor; Child; Child, Preschool; Female; Humans; Indazoles; Mice; Mice, SCID; Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors; Sarcoma, Ewing/drug therapy; Xenograft Model Antitumor Assays

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrimidines / Rhabdomyosarcoma / Sulfonamides / Angiogenesis Inhibitors / Vascular Endothelial Growth Factors / Protein Kinase Inhibitors Type of study: Prognostic_studies Limits: Animals / Child / Child, preschool / Female / Humans Language: En Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google